Other Events ·
EyePoint, Inc. announced the completion of enrollment in two pivotal Phase 3 clinical trials, COMO and CAPRI…
EYPTEyePoint, Inc.
EyePoint, Inc. announced the completion of enrollment in two pivotal Phase 3 clinical trials, COMO and CAPRI, evaluating DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME). The company enrolled over 480 participants across both global trials within five months, ahead of schedule. Topline data from these DME studies is anticipated in the fourth quarter of 2027. This milestone follows a Data Safety Monitoring Committee review that recommended continuing both the DME and wet AMD Phase 3 programs without protocol modifications. EyePoint, Inc. operates as a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.